OmniAb vs PacBio
PacBio reported revenue of $160 million in fiscal 2025, 8.6 times OmniAb's $19 million in fiscal 2025. OmniAb's revenue fell 29.3% in its latest year, and PacBio's grew 3.9%. OmniAb had an operating margin of -369.5%, against -346.1% at PacBio. Free cash flow was −$37 million at OmniAb and −$114 million at PacBio.
Side by side
| OmniAb | PacBio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $19M | $160M |
| Revenue growth | −29.3% | 3.9% |
| Revenue growth a year, last 5 years | — | 15.2% |
| Gross margin | — | 28.6% |
| Operating margin | −369.5% | −346.1% |
| Net margin | −347.0% | −341.5% |
| Free cash flow | −$37M | −$114M |
| Free cash flow margin | −198.3% | −71.2% |
| Return on capital | — | −77.1% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 11.0% | 4.0% |
| Last close | $4.91 | $1.96 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
OmniAbPacBio
Operating margin
Percent of revenue
OmniAbPacBio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
OmniAbPacBio